← All trials
NCT07046975
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2025
- Primary completion
- Jun 30, 2026
- Completion date
- Nov 30, 2026
- First posted
- Jul 2, 2025
- Last posted
- Jul 2, 2025
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sarfez Pharmaceuticals, Inc.Lead sponsor
- Sarfez Pharmaceuticals, Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.